Literature DB >> 9621990

Serum angiogenin levels in children and adolescents with insulin-dependent diabetes mellitus.

A Malamitsi-Puchner1, A Sarandakou, C Dafogianni, J Tziotis, C S Bartsocas.   

Abstract

Microangiopathy, one of the most important complications of diabetes mellitus in humans, is associated with increased angiogenic response and proliferative lesions in various organs. Angiogenin, a polypeptide with a molecular size of 14 kD, is a potent inducer of vascular growth. This study aimed at investigating whether serum angiogenin levels are elevated in children and adolescents (youngsters) with insulin-dependent diabetes mellitus and whether angiogenin levels are affected by duration and metabolic control of the disease. It is assumed that angiogenin levels reflect the increased angiogenesis associated with microangiopathy, whether clinically evident or not. Forty diabetic youngsters were compared with 30 healthy control subjects (mean age +/- SD, 14.3 +/- 3.6 y and 13.8 +/- 3.6 y, respectively). The patients' disease duration and glycosylated Hb were (mean +/- SD) 6.2 +/- 3.8 y and 9.6 +/- 1.8%, respectively. Angiogenin (ng/mL) was measured in serum samples by an enzyme immunoassay and was found to be significantly higher (mean +/- SE) in patients (353.3 +/- 20.0) than in control subjects (244.7 +/- 9.6) (p = 0.0002). Levels did not vary with age, but were significantly higher in females compared with male subjects (p = 0.01). In the diabetic youngsters no significant differences were noticed with respect to duration or metabolic control of the disease. In conclusion, serum angiogenin levels were found to be increased among diabetic youngsters, irrespective of the duration and metabolic control of the disease, as well as in female subjects, with or without diabetes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621990     DOI: 10.1203/00006450-199806000-00013

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats.

Authors:  Jieli Chen; Xinchun Ye; Tao Yan; Chunling Zhang; Xiao-Ping Yang; Xu Cui; Yishen Cui; Alex Zacharek; Cynthia Roberts; Xinfeng Liu; Xiangguo Dai; Mei Lu; Michael Chopp
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

Review 2.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

3.  Estrogen receptor α gene polymorphism and vascular complications in girls with type 1 diabetes mellitus.

Authors:  Bartosz Słomiński; Jolanta Myśliwska; Monika Ryba-Stanisławowska; Maria Skrzypkowska; Małgorzata Myśliwiec
Journal:  Mol Cell Biochem       Date:  2017-06-20       Impact factor: 3.396

Review 4.  The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.

Authors:  Dongdong Yu; Yikai Cai; Wei Zhou; Jinghao Sheng; Zhengping Xu
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

5.  Niaspan attenuates the adverse effects of bone marrow stromal cell treatment of stroke in type one diabetic rats.

Authors:  Tao Yan; Xinchun Ye; Michael Chopp; Alex Zacharek; Ruizhuo Ning; Poornima Venkat; Cynthia Roberts; Mei Lu; Jieli Chen
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

6.  A Pilot Study on MicroRNA Profile in Tear Fluid to Predict Response to Anti-VEGF Treatments for Diabetic Macular Edema.

Authors:  Hwei Wuen Chan; Binxia Yang; Wendy Wong; Paul Blakeley; Ivan Seah; Queenie Shu Woon Tan; Haofei Wang; Mayuri Bhargava; Hazel Anne Lin; Charmaine Hc Chai; Erlangga Ariadarma Mangunkusumo; Naing Thet; Yew Sen Yuen; Raman Sethi; Si Wang; Walter Hunziker; Gopal Lingam; Xinyi Su
Journal:  J Clin Med       Date:  2020-09-10       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.